Selexipag: A New Treatment Agent for Pulmonary Arterial Hypertension

Journal Title: Meandros Medical and Dental Journal - Year 2019, Vol 20, Issue 1

Abstract

Pulmonary arterial hypertension (PAH) is a rare disease which is characterized by the progressive increase of pulmonary arterial pressure. PAH can lead to right cardiac insufficiency and death. Conventional and other treatment modalities that target the physiopathological and etiopathological causes of the disease are currently being used. Selexipag is an oral selective prostacyclin receptor agonist which was developed to overcome the pathophysiological mechanisms that play role in the PAH.

Authors and Affiliations

Onur Yazıcı, Hasan Güngör

Keywords

Related Articles

Rational Use of Drugs Among Inpatients and Its Association with Health Literacy

Objective: Rational use of drugs (RUD) plays a vital role in the success of the treatment process. Considering that use of medicines is also related with decision making mechanisms of individuals, RUD and health literacy...

Oral Precancerous Lesions in Childhood: Attention to the Pediatricians and Pediatric Dentists

Precancerous lesions of oral mucosa, known as premalignant disorders, have greater malignant transform risk concerning dysplastic changes, carcinoma in situ or oral cancers. Oral lichen planus, oral leukoplakia, oral ery...

Evaluation of the Effect of Different Curing Units and Exposure Times on Pulp Chamber Temperature Using Simulated Pulpal Microcirculation

Objective: To compare the elevations in physiological pulp chamber temperature and blood microcirculation during light curing using four different light sources at two different exposure times. Materials and Methods: Th...

Use of Root-end Filling Materials After Root-end Resections Among Oral Surgeons: A National Survey

Objective: The placement of a root-end filling material to seal the end of the root canal is one of the most important procedures in apical surgery. In Turkey, root-end surgeries are most often performed by oral surgeons...

Investigating the Effect of Rosuvastatin, Paracetamol and Co-administration of Rosuvastatin and Paracetamol on Ocular Tissue

Objective: Statins and Paracetamol are two drugs that have a high prescription rate all over the world. Possible side effects can easily be augmented because they use the same cytochrome oxidase enzymes in liver. This st...

Download PDF file
  • EP ID EP48900
  • DOI 10.4274/meandros.galenos.2017.20592
  • Views 330
  • Downloads 0

How To Cite

Onur Yazıcı, Hasan Güngör (2019). Selexipag: A New Treatment Agent for Pulmonary Arterial Hypertension. Meandros Medical and Dental Journal, 20(1), -. https://europub.co.uk/articles/-A-48900